Subcutaneous · GLP-1 / GIP dual
RG7697 / MAR709
1 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
1
Active
0
Recruiting
0
Completed
1
Sites
20
Countries
1
Endpoints
10
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 2
1
Trials by status
Completed
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Glycemic / diabetes
7
Weight & body composition
2
Safety / tolerability / PK
1
Most-measured metrics
Top 20 metrics across this asset's endpoints
HbA1c, changeGlycemic
1
Body weight, absolute change (kg)Weight
1
Body weight, % changeWeight
1
Fasting glucose, changeGlycemic
1
Postprandial glucoseGlycemic
1
C-peptide AUCGlycemic
1
Treatment-emergent AEs (any)Safety/PK
1
HbA1c, % changeGlycemic
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
1 of 1
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT02205528A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin | Liraglutide, RG7697 / MAR709 Obesity / overweight, Type 2 diabetes | — | Ph 2 | Completed | 20 | Sep 2015 | 1 |